{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:44:58Z","timestamp":1792719898905,"version":"4.5.0"},"reference-count":119,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1053\/j.semnuclmed.2025.11.022","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T20:23:04Z","timestamp":1766780584000},"page":"40-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Current status of FAP therapy in solid tumors"],"prefix":"10.1053","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3175-952X","authenticated-orcid":false,"given":"Sophie C.","family":"Siegmund","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1914-1332","authenticated-orcid":false,"given":"Emil","family":"Novruzov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduards","family":"Mamlins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Otto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Canis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Watabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik L.","family":"Giesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.022_bib0001","first-page":"255","article-title":"Radiotheranostics in oncology: making precision medicine possible","volume":"73","author":"Aboagye","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.11.022_bib0002","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"(177)Lu-Dotatate plus long-acting octreotide versus high\u2011dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10446","key":"10.1053\/j.semnuclmed.2025.11.022_bib0003","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1016\/S0140-6736(24)00701-3","volume":"403","author":"Singh","year":"2024","journal-title":"Lancet"},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.11.022_bib0004","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2025.11.022_bib0005","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.2147\/OTT.S140671","article-title":"Theranostics in nuclear medicine practice","volume":"10","author":"Yordanova","year":"2017","journal-title":"Onco Targets Ther"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.11.022_bib0006","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","article-title":"Cancer-associated fibroblasts: from basic science to anticancer therapy","volume":"55","author":"Yang","year":"2023","journal-title":"Exper Molecul Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.022_bib0007","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/nbm.1664","article-title":"Exploiting the tumor microenvironment for theranostic imaging","volume":"24","author":"Stasinopoulos","year":"2011","journal-title":"NMR Biomed"},{"issue":"18","key":"10.1053\/j.semnuclmed.2025.11.022_bib0008","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1073\/pnas.87.18.7235","article-title":"Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers","volume":"87","author":"Garin-Chesa","year":"1990","journal-title":"Proceed Natl Acad Sci"},{"issue":"32","key":"10.1053\/j.semnuclmed.2025.11.022_bib0009","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1038\/s41388-018-0275-3","article-title":"Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics","volume":"37","author":"Pur\u00e9","year":"2018","journal-title":"Oncogene"},{"issue":"5-6","key":"10.1053\/j.semnuclmed.2025.11.022_bib0010","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/prca.201300095","article-title":"Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy","volume":"8","author":"Hamson","year":"2014","journal-title":"Proteom Clin Appl"},{"key":"10.1053\/j.semnuclmed.2025.11.022_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.648187","article-title":"Fibroblast activation protein-\u03b1 as a target in the bench-to-bedside diagnosis and treatment of tumors: A narrative review","volume":"11","author":"Xin","year":"2021","journal-title":"Front Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.022_bib0012","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ygyno.2025.01.010","article-title":"High prevalence of FAP+ cancer-associated fibroblasts predicts poor outcome in patients with high-grade serous ovarian cancer with high CD8 T-cell density","volume":"193","author":"Corvigno","year":"2025","journal-title":"Gynecol Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.022_bib0013","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.lungcan.2021.02.028","article-title":"Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation","volume":"155","author":"Moreno-Ruiz","year":"2021","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.11.022_bib0014","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.85.9.3110","article-title":"Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells","volume":"85","author":"Rettig","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"32","key":"10.1053\/j.semnuclmed.2025.11.022_bib0015","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1038\/sj.onc.1207730","article-title":"FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor","volume":"23","author":"Ramirez-Montagut","year":"2004","journal-title":"Oncogene"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.022_bib0016","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s11886-023-01869-8","article-title":"The potential of fibroblast activation protein-targeted imaging as a biomarker of cardiac remodeling and injury","volume":"25","author":"Mayola","year":"2023","journal-title":"Curr Cardiol Rep"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.11.022_bib0017","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2967\/jnumed.122.264689","article-title":"Fibroblast-activation protein PET and histopathology in a single-center database of 324 patients and 21 tumor entities","volume":"64","author":"Hirmas","year":"2023","journal-title":"J Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.11.022_bib0018","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1053\/j.semnuclmed.2024.05.010","article-title":"Radiomolecular theranostics with fibroblast-activation-protein inhibitors and peptides","volume":"54","author":"Baum","year":"2024","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.022_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fnume.2024.1480471","article-title":"Immunohistochemical basis for FAP as a candidate theranostic target across a broad range of cholangiocarcinoma subtypes","volume":"4","author":"Jorgenson","year":"2024","journal-title":"Front Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0020","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2967\/jnumed.123.266393","article-title":"Immunohistochemical FAP expression reflects (68)Ga-FAPI PET imaging properties of low- and high-grade intraductal papillary mucinous neoplasms and pancreatic ductal adenocarcinoma","volume":"65","author":"Spektor","year":"2024","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.11.022_bib0021","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","article-title":"Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies","volume":"50","author":"Priv\u00e9","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0022","first-page":"44","article-title":"Stromal antigen targeting by a humanised monoclonal antibody: an early phase II trial of sibrotuzumab in patients with metastatic colorectal cancer","volume":"26","author":"Hofheinz","year":"2003","journal-title":"Onkologie"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.11.022_bib0023","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/ml300410d","article-title":"Selective inhibitors of Fibroblast activation protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold","volume":"4","author":"Jansen","year":"2013","journal-title":"ACS Med Chem Lett"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.11.022_bib0024","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.022_bib0025","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.118.215913","article-title":"(68)Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers","volume":"60","author":"Giesel","year":"2019","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.11.022_bib0026","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","article-title":"Development of fibroblast activation protein-targeted radiotracers with improved tumor retention","volume":"60","author":"Loktev","year":"2019","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.11.022_bib0027","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2967\/jnumed.119.236786","article-title":"Radiation dosimetry and biodistribution of (68)Ga-FAPI-46 PET imaging in cancer patients","volume":"61","author":"Meyer","year":"2020","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0028","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s41181-021-00144-x","article-title":"18F-labeled tracers targeting fibroblast activation protein","volume":"6","author":"Lindner","year":"2021","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.11.022_bib0029","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2967\/jnumed.120.245084","article-title":"FAPI-74 PET\/CT using either 18F-AlF or cold-kit 68Ga labeling: biodistribution, radiation dosimetry, and tumor delineation in lung cancer patients","volume":"62","author":"Giesel","year":"2021","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s41181-020-00102-z","article-title":"Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA(5m) chelators","volume":"5","author":"Moon","year":"2020","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.11.022_bib0031","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2967\/jnumed.123.265599","article-title":"Development of FAPI tetramers to improve tumor uptake and efficacy of FAPI radioligand therapy","volume":"64","author":"Pang","year":"2023","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.022_bib0032","first-page":"476","article-title":"Fibroblast Activation protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time","volume":"11","author":"Moon","year":"2021","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0033","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7150\/thno.68182","article-title":"Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics","volume":"12","author":"Wen","year":"2022","journal-title":"Theranostics"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.022_bib0034","doi-asserted-by":"crossref","first-page":"952","DOI":"10.2967\/jnumed.121.262533","article-title":"Albumin binder-conjugated fibroblast activation protein inhibitor radiopharmaceuticals for cancer therapy","volume":"63","author":"Xu","year":"2022","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.022_bib0035","doi-asserted-by":"crossref","first-page":"735","DOI":"10.7150\/thno.23491","article-title":"Evans blue attachment enhances somatostatin receptor subtype-2 imaging and radiotherapy","volume":"8","author":"Tian","year":"2018","journal-title":"Theranostics"},{"issue":"23","key":"10.1053\/j.semnuclmed.2025.11.022_bib0036","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-23-1983","article-title":"Fibroblast activation protein-targeted radioligand therapy with 177Lu-EB-FAPI for metastatic radioiodine-refractory thyroid cancer: first-in-human, dose-escalation study","volume":"29","author":"Fu","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.11.022_bib0037","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1158\/1078-0432.CCR-24-3918","article-title":"177Lu-LNC1004 Radioligand therapy in patients with end-stage metastatic cancers: A single-center, single-arm, phase II study","volume":"31","author":"Fu","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.11.022_bib0038","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","article-title":"Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy","volume":"49","author":"Zboralski","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0039","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/ejic.201900706","article-title":"The use of the macrocyclic chelator DOTA in radiochemical separations","volume":"2020","author":"Baranyai","year":"2020","journal-title":"Eur J Inorgan Chem"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0040","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s41181-023-00196-1","article-title":"Optimization of 177Lu-labelling of DOTA-TOC, PSMA-I&T and FAPI-46 for clinical application","volume":"8","author":"Cankaya","year":"2023","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1053\/j.semnuclmed.2025.11.022_bib0041","doi-asserted-by":"crossref","first-page":"0282","DOI":"10.34133\/research.0282","article-title":"Development and characterization of novel FAP-targeted theranostic pairs: a bench-to-bedside study","volume":"6","author":"Huang","year":"2023","journal-title":"Research"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.022_bib0042","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061889","article-title":"Novel generation of FAP inhibitor-based homodimers for improved application in radiotheranostics","volume":"15","author":"Martin","year":"2023","journal-title":"Cancer (Basel)"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.11.022_bib0043","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s10967-005-0083-4","article-title":"Production of therapeutic radioisotopes in the ORNL High Flux Isotope Reactor (HFIR) for applications in nuclear medicine, oncologyand interventional cardiology","volume":"263","author":"Knapp","year":"2005","journal-title":"J Radioanalyt Nucl Chem"},{"key":"10.1053\/j.semnuclmed.2025.11.022_bib0044","series-title":"Table of Isotopes, 2 Volume Set","author":"Firestone","year":"1998"},{"issue":"2","key":"10.1053\/j.semnuclmed.2025.11.022_bib0045","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s13139-014-0315-z","article-title":"Production of (177)Lu for targeted radionuclide therapy: available options","volume":"49","author":"Dash","year":"2015","journal-title":"Nucl Med Mol Imaging"},{"issue":"1 suppl","key":"10.1053\/j.semnuclmed.2025.11.022_bib0046","first-page":"199S","article-title":"The promise of targeted \u03b1-particle therapy","volume":"46","author":"Mulford","year":"2005","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.11.022_bib0047","first-page":"539","article-title":"Practical guidance on [177Lu]Lu-PSMA-617 treatment, including radiation safety, adverse event monitoring, and patient counseling","volume":"27","author":"Spitz","year":"2023","journal-title":"Clin J Oncol Nurs"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0048","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40658-023-00570-7","article-title":"Individualisation of radiation protection recommendations for patients treated with [177Lu]Lu-DOTA-TATE","volume":"10","author":"Monserrat Fuertes","year":"2023","journal-title":"EJNMMI Phys"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0049","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00259-024-06795-7","article-title":"Feasibility and therapeutic potential of [(177)Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma","volume":"52","author":"Banihashemian","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.11.022_bib0050","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.022_bib0051","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"(68)Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"issue":"supplement 1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0052","article-title":"Intensity of tracer-uptake in FAPI-PET\/CT in different kinds of cancer","volume":"60","author":"Giesel","year":"2019","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.11.022_bib0053","first-page":"15","article-title":"Head-to-Head intra-individual comparison of biodistribution and tumor uptake of [(18)F]FAPI-74 with [(18)F]FDG in patients with PDAC: A prospective exploratory study","author":"Novruzov","year":"2023","journal-title":"Cancer (Basel)"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.11.022_bib0054","doi-asserted-by":"crossref","first-page":"3963","DOI":"10.1007\/s00259-025-07239-6","article-title":"68Ga-FAPI and 18F-FAPI PET\/CT for detection of nodal metastases prior radical cystectomy in high-risk urothelial carcinoma patients","volume":"52","author":"Unterrainer","year":"2025","journal-title":"Eur J Nucl Med Molecul Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0055","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13643-025-02835-x","article-title":"Revolutionizing cancer diagnosis and dose biodistribution: a meta-analysis of [68ga] FAPI- 46 vs. [18f] FDG imaging","volume":"14","author":"Abbasi","year":"2025","journal-title":"Syst Rev"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.11.022_bib0056","article-title":"Head-to-Head comparison of FDG and radiolabeled FAPI PET: A systematic review of the literature","volume":"13","author":"Guglielmo","year":"2023","journal-title":"Life (Basel)"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.022_bib0057","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2967\/jnumed.123.266652","article-title":"Diagnostic accuracy of 68Ga-FAPI versus 18F-FDG PET in patients with various malignancies","volume":"65","author":"Hirmas","year":"2024","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0058","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13139-017-0493-6","article-title":"Current methods to define metabolic tumor volume in positron emission tomography: which one is better?","volume":"52","author":"Im","year":"2018","journal-title":"Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0059","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s44303-024-00053-z","article-title":"Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET)","volume":"2","author":"Mori","year":"2024","journal-title":"npj Imaging"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.022_bib0060","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1007\/s11307-022-01749-7","article-title":"Head-to-Head comparison of [(68) Ga]Ga-FAPI-46-PET\/CT and [(18)F]F-FDG-PET\/CT for radiotherapy planning in Head and neck cancer","volume":"24","author":"Wegen","year":"2022","journal-title":"Mol Imaging Biol"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.022_bib0061","doi-asserted-by":"crossref","first-page":"890","DOI":"10.2967\/jnumed.121.262808","article-title":"Pitfalls and common findings in 68Ga-FAPI PET: A pictorial analysis","volume":"63","author":"Kessler","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2025.11.022_bib0062","article-title":"Meeting upcoming clinical and diagnostic needs in oncologic imaging: a structured reporting system for fibroblast-activation-Protein\u2013Targeted Imaging\u2014FAP-RADS Version 1.0","volume":"125","author":"Novruzov","year":"2025","journal-title":"J Nucl Med"},{"issue":"supplement 2","key":"10.1053\/j.semnuclmed.2025.11.022_bib0063","article-title":"Comparison of early response assessment with Ga-68 FAPI PET\/CT and F-18 FDG PET\/CT in non-small cell lung cancer","volume":"65","author":"Mittal","year":"2024","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.11.022_bib0064","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1007\/s00259-025-07271-6","article-title":"18F]FAPI- 04 PET\/CT for pathologic response assessment in pancreatic cancer patients with systemic treatment","volume":"52","author":"Li","year":"2025","journal-title":"Eur J Nucl Med Molecul Imaging"},{"key":"10.1053\/j.semnuclmed.2025.11.022_bib0065","doi-asserted-by":"crossref","first-page":"S526","DOI":"10.1016\/j.annonc.2024.08.737","article-title":"671P LuMIERE: A phase I\/II study evaluating safety, dosimetry, and preliminary activity of [177Lu]Lu-FAP-2286 in patients with advanced solid tumors","volume":"35","author":"McConathy","year":"2024","journal-title":"Annal Oncol"},{"key":"10.1053\/j.semnuclmed.2025.11.022_bib0066","unstructured":"LuMIERE: A Phase 1\/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor. 2021."},{"issue":"12","key":"10.1053\/j.semnuclmed.2025.11.022_bib0067","doi-asserted-by":"crossref","DOI":"10.3390\/ph14121212","article-title":"First-In-Human results on the biodistribution, pharmacokinetics, and dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)","volume":"14","author":"Ballal","year":"2021","journal-title":"Pharmaceut (Basel)"},{"key":"10.1053\/j.semnuclmed.2025.11.022_bib0068","article-title":"Efficacy and safety of177Lu-DOTAGA.Glu.(FAPi)2Therapy in patients with Sarcoma","volume":"125","author":"Ballal","year":"2025","journal-title":"J Nucl Med"},{"issue":"supplement 1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0069","article-title":"Efficacy and safety of [177Lu]Lu-DOTAGA.Glu(FAPi)\u2082 therapy in patients with Sarcoma","volume":"66","author":"Mohammad","year":"2025","journal-title":"J Nucl Med"},{"issue":"supplement 2","key":"10.1053\/j.semnuclmed.2025.11.022_bib0070","article-title":"FRONTIER: FAPi Radioligand OpeN-label, phase 1 study to evaluate safety, tolerability and dosImetry of [Lu-177]-PNT6555; a dose escalation study for tReatment of patients with select solid tumors","volume":"65","author":"Juneau","year":"2024","journal-title":"J Nucl Med"},{"issue":"supplement 1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0071","article-title":"Intraindividual tumor dosimetry of monomer [90Y]Y-FAPI-46 vs dimer [90Y]Y-DOTAGA-Glu-(FAPI)2 FAP radioligand therapy of advanced stage solid tumors","volume":"66","author":"Fragoso costa","year":"2025","journal-title":"J Nucl Med"},{"issue":"supplement 2","key":"10.1053\/j.semnuclmed.2025.11.022_bib0072","article-title":"Initial clinical experience with 177Lu-EB-FAPI radioligand therapy in patients with end-stage metastatic cancers","volume":"65","author":"Fu","year":"2024","journal-title":"J Nucl Med"},{"issue":"supplement 1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0073","article-title":"Safety, feasibility, and dosimetry of 177Lu-EB-FAPI radioligand therapy with escalating doses in metastatic radioiodine refractory thyroid cancer","volume":"64","author":"Fu","year":"2023","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.022_bib0074","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using (177)Lu-FAP-2286: first-in-humans results","volume":"63","author":"Baum","year":"2022","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.11.022_bib0075","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.2967\/jnumed.124.267452","article-title":"Dosimetry of [(177)Lu]Lu-PSMA-targeted radiopharmaceutical therapies in patients with prostate cancer: a comparative systematic review and metaanalysis","volume":"65","author":"Ells","year":"2024","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0076","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2967\/jnumed.124.269002","article-title":"SNMMI procedure standard\/EANM practice guideline for fibroblast activation protein (FAP) PET","volume":"66","author":"Hope","year":"2025","journal-title":"J Nucl Med"},{"issue":"supplement 1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0077","article-title":"Efficacy and safety of [177Lu]Lu-DOTAGA.FAPi dimer radionuclide therapy in patients with advanced-stage breast cancer","volume":"64","author":"Yadav","year":"2023","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.11.022_bib0078","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1007\/s00259-021-05634-3","article-title":"FAP-targeted radionuclide therapy with [(177)Lu]Lu-FAPI-46 in metastatic nasopharyngeal carcinoma","volume":"49","author":"Fu","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.11.022_bib0079","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1097\/RLU.0000000000003810","article-title":"Feasibility and therapeutic potential of 177Lu-fibroblast activation protein inhibitor-46 for patients with relapsed or refractory cancers: A preliminary study","volume":"46","author":"Assadi","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0080","first-page":"65","article-title":"Novel fibroblast activation protein inhibitor-based targeted theranostics for radioiodine-refractory differentiated thyroid cancer patients: A pilot study","volume":"32","author":"Ballal","year":"2022","journal-title":"Thyroid"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.022_bib0081","doi-asserted-by":"crossref","first-page":"e444","DOI":"10.1097\/RLU.0000000000004164","article-title":"First-in-Human experience with 177Lu-DOTAGA.(SA.FAPi)2 therapy in an uncommon case of aggressive medullary thyroid carcinoma clinically mimicking as anaplastic thyroid cancer","volume":"47","author":"Ballal","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"supplement 1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0082","article-title":"Efficacy and safety of [177Lu]Lu-DOTAGA.Glu(FAPi)\u2082 therapy in patients with radioiodine-resistant follicular cell-derived thyroid cancers <\/strong>","volume":"66","author":"Ballal","year":"2025","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.022_bib0083","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00259-023-06482-z","article-title":"Therapeutic potential of [(177)Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: efficacy and safety assessment","volume":"51","author":"Yadav","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2025.11.022_bib0084","doi-asserted-by":"crossref","unstructured":"Zhang, J., et al., Fibroblast activating protein (FAP)-targeted radiopeptide therapy using 177Lu-, 225Ac- and 90Y-labeled 3BP-3940 in diverse advanced solid tumors: first-in-humans results. Vol. 62. 2023.","DOI":"10.1055\/s-0043-1766155"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.022_bib0085","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/RLU.0000000000005169","article-title":"Metastatic lung adenocarcinoma received combined 177 Lu-FAP-2286 radiation therapy and targeted therapy","volume":"49","author":"Yang","year":"2024","journal-title":"Clin Nucl Med"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.11.022_bib0086","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1007\/s00259-022-06048-5","article-title":"[(177)Lu]Lu-FAP-2286 therapy in a case of right lung squamous cell carcinoma with systemic metastases","volume":"50","author":"Rao","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.022_bib0087","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1097\/RLU.0000000000004021","article-title":"177Lu-FAPI therapy in a patient with end-stage metastatic pancreatic adenocarcinoma","volume":"47","author":"Kaghazchi","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"supplement 1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0088","article-title":"FAP-directed radiopharmaceutical therapy of metastatic pancreas adenocarcinoma with alpha-emitting Actinium-225 or in TANDEM","volume":"66","author":"Perrone","year":"2025","journal-title":"J Nucl Med"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.11.022_bib0089","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1097\/RLU.0000000000004865","article-title":"177 Lu-FAP-2286 therapy in a case of recurrent bladder cancer with multiple metastatic lesions","volume":"48","author":"Li","year":"2023","journal-title":"Clin Nucl Med"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.022_bib0090","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1016\/S1470-2045(24)00030-5","article-title":"Recent advances and impending challenges for the radiopharmaceutical sciences in oncology","volume":"25","author":"Lapi","year":"2024","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.11.022_bib0091","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1097\/RLU.0000000000005255","article-title":"First experience of radionuclide therapy with 177Lu-FAPI-2286 in a patient with metastatic mediastinal sarcoma","volume":"49","author":"Banihashemian","year":"2024","journal-title":"Clin Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.022_bib0092","doi-asserted-by":"crossref","first-page":"276","DOI":"10.4103\/ijnm.ijnm_22_23","article-title":"Ga68-FAPI imaging and Lu177-FAPI therapy in a case of metastatic solitary fibrous tumor","volume":"38","author":"Luthra","year":"2023","journal-title":"India J Nucl Med"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.022_bib0093","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1007\/s00259-020-04990-w","article-title":"A theranostic approach of [(68)Ga]Ga-DOTA.SA.FAPi PET\/CT-guided [(177)Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy","volume":"48","author":"Ballal","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.11.022_bib0094","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s00259-023-06211-6","article-title":"Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition","volume":"50","author":"Zboralski","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0095","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010212","article-title":"FAP-targeted radioligand therapy with (68)Ga\/(177)Lu-DOTA-2P(FAPI)(2) enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy","volume":"13","author":"Chen","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0096","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41392-024-01853-w","article-title":"Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade","volume":"9","author":"Zhao","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"10.1053\/j.semnuclmed.2025.11.022_bib0097","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106600","article-title":"FAP promotes metastasis and chemoresistance via regulating YAP1 and macrophages in mucinous colorectal adenocarcinoma","volume":"26","author":"Ji","year":"2023","journal-title":"iScience"},{"issue":"13","key":"10.1053\/j.semnuclmed.2025.11.022_bib0098","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1007\/s00259-024-06817-4","article-title":"The complete metabolic\/molecular response to chemotherapy combined with [(177)Lu]Lu-FAP-2286 in metastatic breast cancer","volume":"51","author":"Banihashemian","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1053\/j.semnuclmed.2025.11.022_bib0099","doi-asserted-by":"crossref","DOI":"10.1016\/j.bj.2024.100744","article-title":"The synergy of (177)Lu-FAPI-46 with tyrosine kinase inhibitor in a sarcoma patient-derived xenograft mouse model","volume":"47","author":"Tseng","year":"2024","journal-title":"Biomed J"},{"issue":"9","key":"10.1053\/j.semnuclmed.2025.11.022_bib0100","doi-asserted-by":"crossref","first-page":"e547","DOI":"10.1097\/RLU.0000000000005723","article-title":"Combination therapy with 177 Lu-FAPI-2286 and tyrosine kinase inhibitor: A novel approach for treating metastatic medullary thyroid carcinoma","volume":"50","author":"Raeisi","year":"2025","journal-title":"Clin Nucl Med"},{"issue":"11","key":"10.1053\/j.semnuclmed.2025.11.022_bib0101","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113108","article-title":"Cancer-associated fibroblasts: understanding their heterogeneity","volume":"12","author":"Louault","year":"2020","journal-title":"Cancer (Basel)"},{"issue":"5","key":"10.1053\/j.semnuclmed.2025.11.022_bib0102","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/jso.27582","article-title":"Myofibroblastic cancer-associated fibroblast subtype heterogeneity in pancreatic cancer","volume":"129","author":"Kearney","year":"2024","journal-title":"J Surg Oncol"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0103","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12964-023-01125-0","article-title":"What is new in cancer-associated fibroblast biomarkers?","volume":"21","author":"Zhao","year":"2023","journal-title":"Cell Commun Signal"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0104","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/s41467-025-57465-7","article-title":"Antigen-presenting cancer associated fibroblasts enhance antitumor immunity and predict immunotherapy response","volume":"16","author":"Song","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0105","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1038\/s41467-023-39762-1","article-title":"Cancer-associated fibroblast classification in single-cell and spatial proteomics data","volume":"14","author":"Cords","year":"2023","journal-title":"Nat Commun"},{"issue":"24","key":"10.1053\/j.semnuclmed.2025.11.022_bib0106","doi-asserted-by":"crossref","first-page":"5330","DOI":"10.1158\/1078-0432.CCR-22-1379","article-title":"Monitoring therapeutic response to anti-FAP CAR T cells using [18F]AlF-FAPI-74","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.semnuclmed.2025.11.022_bib0107","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217475","article-title":"FAP upregulates PD-L1 expression in cancer-associated fibroblasts to exacerbate T cells dysfunction and suppress anti-tumor immunity","volume":"612","author":"Wei","year":"2025","journal-title":"Cancer Lett"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.11.022_bib0108","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jcmgh.2022.12.005","article-title":"Fibroblast activation protein activates macrophages and promotes parenchymal liver inflammation and fibrosis","volume":"15","author":"Yang","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"supplement 1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0109","article-title":"FAP PET\/CT imaging in radiation induced pulmonary fibrosis","volume":"64","author":"Medina Guevara","year":"2023","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0110","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00259-024-06891-8","article-title":"Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [(68)Ga]Ga-\/[(18)F]F-PSMA-11\/-1007, [(68)Ga]Ga-FAPI-46 and 2-[(18)F]FDG PET\/CT: a pilot study","volume":"52","author":"Pabst","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"10.1053\/j.semnuclmed.2025.11.022_bib0111","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1007\/s00259-024-06809-4","article-title":"Evaluating [(225)Ac]Ac-FAPI-46 for the treatment of soft-tissue sarcoma in mice","volume":"51","author":"Taddio","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"10.1053\/j.semnuclmed.2025.11.022_bib0112","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1021\/cbmi.3c00067","article-title":"225Ac-Labeled antibody for fibroblast activation protein-targeted alpha therapy","volume":"1","author":"Song","year":"2023","journal-title":"Chem Biomed Imaging"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.11.022_bib0113","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1007\/s00259-022-05778-w","article-title":"Hematologic toxicity profile and efficacy of [(225)Ac]Ac-PSMA-617 \u03b1-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer","volume":"49","author":"Lawal","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1053\/j.semnuclmed.2025.11.022_bib0114","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2967\/jnumed.119.233122","article-title":"Theranostics targeting fibroblast activation protein in the tumor stroma: (64)Cu- and (225)Ac-labeled FAPI-04 in pancreatic cancer xenograft mouse models","volume":"61","author":"Watabe","year":"2020","journal-title":"J Nucl Med"},{"issue":"8","key":"10.1053\/j.semnuclmed.2025.11.022_bib0115","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.2967\/jnumed.122.265291","article-title":"161Tb-PSMA radioligand Therapy: first-in-humans SPECT\/CT imaging","volume":"64","author":"Al-Ibraheem","year":"2023","journal-title":"J Nucl Med"},{"issue":"supplement 1","key":"10.1053\/j.semnuclmed.2025.11.022_bib0116","article-title":"First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase I\/II study","volume":"66","author":"Buteau","year":"2025","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1053\/j.semnuclmed.2025.11.022_bib0118","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24108701","article-title":"Evaluation of astatine-211-labeled fibroblast activation protein inhibitor (FAPI): comparison of different linkers with polyethylene glycol and piperazine","volume":"24","author":"Aso","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"8015","key":"10.1053\/j.semnuclmed.2025.11.022_bib0119","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41586-024-07461-6","article-title":"Covalent targeted radioligands potentiate radionuclide therapy","volume":"630","author":"Cui","year":"2024","journal-title":"Nature"},{"key":"10.1053\/j.semnuclmed.2025.11.022_bib0120","series-title":"Covalent FAPI PET Enables Accurate Management of Medullary Thyroid Carcinoma: a Prospective Single-arm Comparative Clinical Trial","author":"Kong","year":"2024"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825001771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299825001771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T05:09:13Z","timestamp":1771218553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299825001771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":119,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0001299825001771"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.11.022","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current status of FAP therapy in solid tumors","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2025.11.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}